MicroRNA‑765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6

  • Authors:
    • Shifeng Long
    • Shengping Long
    • Honglei He
    • Guoan Chen
  • View Affiliations

  • Published online on: April 10, 2019     https://doi.org/10.3892/etm.2019.7473
  • Pages: 4741-4747
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Increasing evidence has revealed that microRNAs (miRNAs) are closely associated with multiple myeloma (MM) pathogenesis and progression. Therefore, an in‑depth understanding of the biological functions of miRNAs in MM may be helpful for the identification of promising therapeutic techniques for patients with MM. miRNA‑765 (miR‑765) has been reported to be dysregulated in many types of human cancer. However, the expression pattern, specific roles and underlying mechanisms of miR‑765 in MM remain largely unknown. In the present study, plasma miR‑765 significantly increased in patients with MM and cell lines. The downregulation of miR‑765 in MM cells attenuated proliferation and promoted apoptosis. Bioinformatics analysis predicted that SRY‑Box 6 (SOX6) was a putative target of miR‑765. This was experimentally verified using a luciferase reporter assay, reverse transcription‑quantitative PCR and western blot analysis. Furthermore, plasma SOX6 was downregulated in patients with MM and the downregulation of SOX6 was inversely correlated with that of miR‑765 expression. Furthermore, SOX6 knockdown markedly abrogated the effects of miR‑765 underexpression on cell proliferation and apoptosis in MM. The current study demonstrated that miR‑765 serves an oncogenic role in MM progression by directly targeting SOX6, suggesting that miR‑765 may be a potential therapeutic target for MM prevention and treatment.

References

1 

Anderson KC and Carrasco RD: Pathogenesis of myeloma. Annu Rev Pathol. 6:249–274. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Pruneri G, Cinieri S, Peccatori F and Viale G: Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 2. Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow. J Clin Oncol. 23:232–233. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Naymagon L and Abdul-Hay M: Novel agents in the treatment of multiple myeloma: A review about the future. J Hematol Oncol. 9:522016. View Article : Google Scholar : PubMed/NCBI

4 

Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, et al: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 26:149–157. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Jiang S, Hu C, Liu P and Lu M: Tumor-derived exosomes in cancer metastasis risk diagnosis and metastasis therapy. Clin Transl Oncol. 21:152–159. 2019. View Article : Google Scholar : PubMed/NCBI

8 

Yuan HL, Wang T and Zhang KH: MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther. 11:3891–3900. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Sharma N and Baruah MM: The microRNA signatures: Aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 21:126–144. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X and Cong H: The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. Oncol Lett. 15:6094–6106. 2018.PubMed/NCBI

11 

Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C and Neri A: Long Non-Coding RNAs in multiple myeloma. Genes (Basel). 9(pii): E692018. View Article : Google Scholar : PubMed/NCBI

12 

Rastgoo N, Abdi J, Hou J and Chang H: Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. J Hematol Oncol. 10:1212017. View Article : Google Scholar : PubMed/NCBI

13 

Yang YZ, Zhang XY, Wan Q and Li J: Role of Exosomal miRNA in multiple myeloma progression and its possible mechanism-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 25:301–305. 2017.(In Chinese). PubMed/NCBI

14 

Rossi M, Tagliaferri P and Tassone P: MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med. 3:3342015.PubMed/NCBI

15 

Bi C and Chng WJ: MicroRNA: Important player in the pathobiology of multiple myeloma. Biomed Res Int. 2014:5215862014. View Article : Google Scholar : PubMed/NCBI

16 

Cao Y, Shi X, Liu Y, Xu R and Ai Q: MicroRNA-338-3p inhibits proliferation and promotes apoptosis of multiple myeloma cells through targeting Cyclin-dependent kinase 4. Oncol Res. 27:117–124. 2018. View Article : Google Scholar : PubMed/NCBI

17 

Tang B, Xu A, Xu J, Huang H, Chen L, Su Y, Zhang L, Li J, Fan F, Deng J, et al: MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Int J Cancer. 142:109–120. 2018. View Article : Google Scholar : PubMed/NCBI

18 

Alzrigat M and Jernberg-Wiklund H: The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis. 4(pii): e15292017.PubMed/NCBI

19 

Zhang X, Chen Y, Zhao P, Zang L, Zhang Z and Wang X: MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. Leuk Lymphoma. 58:932–940. 2017. View Article : Google Scholar : PubMed/NCBI

20 

Hua J, Ding T and Yang L: Dysfunction of microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma disease. Onco Targets Ther. 9:6573–6579. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Ikeda S, Kitadate A, Abe F, Saitoh H, Michishita Y, Hatano Y, Kawabata Y, Kitabayashi A, Teshima K, Kume M, et al: Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. Cancer Sci. 108:641–652. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Liu Z, Zhang G, Yu W, Gao N and Peng J: miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. Biochem Biophys Res Commun. 469:692–697. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Saha MN, Abdi J, Yang Y and Chang H: MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget. 7:7149–7160. 2016. View Article : Google Scholar : PubMed/NCBI

24 

Jiang B, Xu G, Lv HQ, Huang M and Li Z: Up-regulation of miR-765 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 22:3789–3794. 2018.PubMed/NCBI

25 

Liang W, Wei X, Li Q, Dai N, Li CY, Deng Y, Jiang X, Tan XR, Dai XY, Li MX, et al: MicroRNA-765 enhances the anti-angiogenic effect of CDDP via APE1 in Osteosarcoma. J Cancer. 8:1542–1551. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Xie BH, He X, Hua RX, Zhang B, Tan GS, Xiong SQ, Liu LS, Chen W, Yang JY, Wang XN and Li HP: Mir-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma. Cancer Biomark. 16:405–413. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Wang Z, Li J, Li K and Xu J: SOX6 is downregulated in osteosarcoma and suppresses the migration, invasion and epithelial-mesenchymal transition via TWIST1 regulation. Mol Med Rep. 17:6803–6811. 2018.PubMed/NCBI

29 

Li Y, Xiao M and Guo F: The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis. Tumour Biol. 39:10104283177055082017.PubMed/NCBI

30 

Zhu Y, Xia Y, Niu H and Chen Y: MiR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma. Cell Physiol Biochem. 33:1340–1348. 2014. View Article : Google Scholar : PubMed/NCBI

31 

Yang Y, Li F, Saha MN, Abdi J, Qiu L and Chang H: miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 21:2399–2411. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J, Li J and Chen L: Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol. 31:2192014. View Article : Google Scholar : PubMed/NCBI

33 

Ma J, Liu S and Wang Y: MicroRNA-21 and multiple myeloma: Small molecule and big function. Med Oncol. 31:942014. View Article : Google Scholar : PubMed/NCBI

34 

Hu Y, Wang H, Chen E, Xu Z, Chen B and Lu G: Candidate microRNAs as biomarkers of thyroid carcinoma: A systematic review, meta-analysis, and experimental validation. Cancer Med. 5:2602–2614. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Ding J, Yang C and Yang S: LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2. J Oral Pathol Med. 47:468–476. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Ohta S, Misawa A, Lefebvre V, Okano H, Kawakami Y and Toda M: Sox6 up-regulation by macrophage migration inhibitory factor promotes survival and maintenance of mouse neural stem/progenitor cells. PLoS One. 8:e743152013. View Article : Google Scholar : PubMed/NCBI

37 

Jiang W, Yuan Q, Jiang Y, Huang L, Chen C, Hu G, Wan R, Wang X and Yang L: Identification of Sox6 as a regulator of pancreatic cancer development. J Cell Mol Med. 22:1864–1872. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Yu Y, Wang Z, Sun D, Zhou X, Wei X, Hou W, Ding Y, Ma Y and Hou Y: miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor SOX6. Eur J Pharmacol. 823:65–71. 2018. View Article : Google Scholar : PubMed/NCBI

39 

Li YC, Li CF, Chen LB, Li DD, Yang L, Jin JP and Zhang B: MicroRNA-766 targeting regulation of SOX6 expression promoted cell proliferation of human colorectal cancer. Onco Targets Ther. 8:2981–2988. 2015. View Article : Google Scholar : PubMed/NCBI

40 

Guo X, Yang M, Gu H, Zhao J and Zou L: Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma. Cancer Epidemiol. 37:732–736. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Long, S., Long, S., He, H., & Chen, G. (2019). MicroRNA‑765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6. Experimental and Therapeutic Medicine, 17, 4741-4747. https://doi.org/10.3892/etm.2019.7473
MLA
Long, S., Long, S., He, H., Chen, G."MicroRNA‑765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6". Experimental and Therapeutic Medicine 17.6 (2019): 4741-4747.
Chicago
Long, S., Long, S., He, H., Chen, G."MicroRNA‑765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4741-4747. https://doi.org/10.3892/etm.2019.7473